Cited by 765Pharmaceutical industry and healthcareHealth and Medical Research ImpactsPharmaceutical Economics and Policy

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Uneasy alliance—clinical investigators and the pharmaceutical industry

Bodenheimer, Thomas·2000·New England Journal of Medicine

DOI 10.1056/nejm200005183422024

Open this paper in CoChat — free account

Abstract

Clinical practice is changing rapidly. New cardiovascular drugs, antiinflammatory drugs, cancer chemotherapy, and other pharmacologic weapons are being added to physicians' therapeutic armamentarium virtually daily. Most clinical studies that bring new drugs from bench to bedside are financed by pharmaceutical companies. Many of these drug trials are rigorously designed, employing the skills of outstanding clinical researchers at leading academic institutions.But academic medical centers are no longer the sole citadels of clinical research. The past 10 years have seen the spectacular growth of a new research model. Commercially oriented networks of contract-research organizations (CROs) and site-management organizations (SMOs) have altered . . .

Integrity signals

Registry

Crossref · 10.1056/nejm200005183422024

Cites

0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Conflict of Interest in the Debate over Calcium-Channel Antagonists
Stelfox, H. T., Chua, G., O'Rourke, K., & Detsky, A. S. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801083380206 · Cited by 615
Source of funding and outcome of clinical trials
Davidson, R. A. (1986) · Journal of General Internal Medicine · doi:10.1007/bf02602327 · Cited by 397
Problems in the Design and Reporting of Trials of Antifungal Agents Encountered During Meta-analysis
Johansen, H. K. (1999) · JAMA · doi:10.1001/jama.282.18.1752 · Cited by 128

Show all 0 references

Research works printed but not linked: 29

Cho MK, 1996, Ann Intern Med, 124, 485, 10.7326/0003-4819-124-5-199603010-00004 · DOI
10.1001/jama.282.15.1453 · DOI
Chow S-C, Liu J-P. Design and analysis of clinical trials. New York: John Wiley, 1998.
10.1001/jama.282.8.786 · DOI
10.1001/jama.282.20.1947 · DOI
1997, CenterWatch, 4, 1, 9
Henderson L, 1999, CenterWatch, 6, 1, 4
Vogel JR, 1999, Appl Clin Trials, 8, 56
1997, CenterWatch, 4, 1
10.1017/S0266462300009582 · DOI
Rochon PA, 1998, CMAJ, 159, 1373
10.1001/archinte.154.2.157 · DOI
10.1001/jama.282.8.790 · DOI
10.1001/jama.277.15.1224 · DOI
10.1001/jama.263.10.1405 · DOI
10.1056/NEJM199808133390701 · DOI
Phillips RA, 1998, CMAJ, 159, 955
10.1001/jama.277.15.1238 · DOI
10.1001/jama.277.4.297a · DOI
10.1016/S0140-6736(05)75272-7 · DOI
10.1016/S0140-6736(05)80075-3 · DOI
10.1001/jama.271.6.469 · DOI
10.1056/NEJM199409083311012 · DOI
10.1001/jama.280.3.222 · DOI · Paper page
10.1001/jama.277.11.927 · DOI
10.1056/NEJM199812173392512 · DOI
Kunin CM, 1978, Ann Intern Med, 89, 842, 10.7326/0003-4819-89-5-842 · DOI
10.1001/jama.278.3.245 · DOI
10.1056/NEJM200005183422009 · DOI

Sorted by citations

Items 501–600 of 641

Conflicts of interest policies and disclosure requirements among European Society of Cardiology national cardiovascular journals
Alfonso, F., Timmis, A., Pinto, F. J., Ambrosio, G., Ector, H., Kułakowski, P., & Vardas, P. E. (2012) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0b013e328354a803 · Cited by 2
Conflict of Interest Policies and Disclosure Requirements Among European Society of Cardiology National Cardiovascular Journals
Alfonso, F., Timmis, A., Pinto, F. J., Ambrosio, G., Ector, H., Kułakowski, P., Vardas, P. E., & on behalf of the Editors' Network European Society of Cardiology Task Force (2012) · Circulation Journal · doi:10.1253/circj.cj-66-0045 · Cited by 7
“28 This could be a result of their ability to complete trials more rapidly than academic institutions.(8,25) This phenomenon explains the gradual loss of the academic establishment’s influence on the ‘research agenda’.”
Background
9. Pharmacoepidemiology and the Law
Kesselheim, A. (2012) · Pharmacoepidemiology · doi:10.1002/9781119959946.ch9 · Cited by 1
Collaboration in research protocol design: A case study exploring knowledge creation for the pharmaceutical industry and prescribing physicians
Richards, D., & Dalton, B. (2009) · doi:10.1057/jmm.2009.20 · Cited by 1
Academic freedom, scientific integrity, and conflicts of interest: Lessons learned from the University of Toronto
Olivieri, N. (2008) · doi:10.5779/hypothesis.v3i2.35 · Cited by 1
“There is empirical evidence that such heavy involvement of industry in biomedical research may negatively influence scientific integrity (11).”
Background
The Emperor's New Clothes or the Current Practice of Clinical Trials for Multiple Myeloma in the USA
Ballester, O. (2008) · Cancer Investigation · doi:10.1080/07357900701874641 · Cited by 1
“The dangers of industry/academia close relationships have been extensively discussed elsewhere (11).”
Background
Le mète per un'ecologia della ricerca clinica
Liberati, A., Moja, L., & Moschetti, I. (2006) · Recenti progressi in medicina · doi:10.1701/185.1951 · Cited by 1
Study design and rationale of a mock phase I trial as an educational tool for clinical pharmacology residents.
Malhotra, S., Shafiq, N., Chandra, K., Pandhi, P., & Grover, A. (2006) · Contemporary Clinical Trials · doi:10.1016/j.cct.2005.10.002 · Cited by 1
“Studies are done increasingly by for-profit organizations rather than by academic medical centers (60% in 1998 vs 20% in 1991) [8].”
Background
THE EFFECT OF RISPERIDONE ON NURSING BURDEN ASSOCIATED WITH CARING FOR PATIENTS WITH DEMENTIA
Asghar-Ali, A., Espinoza, R., Kavirajan, H. C., & Read, S. (2005) · Journal of The American Geriatrics Society · doi:10.1111/j.1532-5415.2005.53384_3.x · Cited by 1
A Review of: “Ezekiel J. Emanuel, Robert A. Crouch, John D. Arras, et al., eds. 2004. Ethical and Regulatory Aspects of Clinical Research: Readings and Commentary”
Mann, H. (2005) · The American Journal of Bioethics · doi:10.1080/15265160591002980
“” The conduct of clinical research today is characterized by a pervasive entrepreneurialism ( Krimsky 2003 ), troubling alliances between academics and the pharmaceutical industry ( Bodenheimer 2000 ), and biased assessments of the efficacy of medical interventions plausibly attributable to financial relationships wit…”
Background
Ethical Issues in Drug Safety
Stephens, M. (2005) · doi:10.1002/0470014199.ch15 · Cited by 1
Conflicts of Interest in Biomedical Research Harm Children With and Without Disabilities
Sharav, V. H. (2004) · Journal of Disability Policy Studies · doi:10.1177/10442073040150010801 · Cited by 1
“Powerful institutions whose interests conflict with those of research subjects control all facets of research, including the approval process (Angell, 2000; Bodenheimer, 2000; Kassirer, 2001; Relman & Angell, 2002).”
Background
Industry and Academic Medicine: A Dangerous Liaison?
Norris, J. (2004) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s031716710000278x · Cited by 1
Assessing 'real science': poor studies, industry ties taking toll.
Hamilton, J. (2004) · Journal - California Dental Association · doi:10.1080/19424396.2004.12223942 · Cited by 1
Kooperation statt Korruption
Beyer, J., Frewer, A., Kingreen, D., Meran, J., & Neubauer, A. (2003) · Der Onkologe · doi:10.1007/s00761-003-0609-8 · Cited by 1
More bad news about money and medical science
Fielder, J. (2003) · IEEE Engineering in Medicine and Biology Magazine · doi:10.1109/memb.2003.1195704 · Cited by 1
Misconduct in medical research: ethics and democracy
Komesaroff, P. A. (2003) · Internal medicine journal (Print) · doi:10.1046/j.1445-5994.2003.00372.x · Cited by 1
Can a doctor enjoy a medical company's generosity without prescribing its products?
Worthley, L. (2002) · Critical Care and Resuscitation · doi:10.1016/s1441-2772(23)01197-3 · Cited by 1
Gastroenterology and the pharmaceutical industry
Rakatansky, H. (2002) · doi:10.1046/j.1365-2036.2002.01362.x · Cited by 1
Scientific Data from Clinical Trials: Investigators’ Responsibilities and Rights
Büchler, M., & Neoptolemos, J. (2002) · Digestive Surgery · doi:10.1159/000064205 · Cited by 1
Scientific data from clinical trials: investigators' responsibilities and rights
Polk, H., Bowden, T., Rikkers, L., Balch, C., Murie, J., Pories, W., Buechler, M., Neoptolemos, J., Fazio, V., Schwartz, S., et al. (2002) · Journal of Trauma · doi:10.1046/j.1365-2168.2002.02124.x · Cited by 1
Article Commentary: Independent Clinical Trials: A Commentary
Cocconi, G. (2002) · Tumori · doi:10.1177/030089160208800201 · Cited by 1
Ethical Considerations in Clinical Trials in Asia
Tanida, N. (2002) · Drug Information Journal · doi:10.1177/009286150203600108
“Issues of for-profit multinational research subject recruiting activity, utility of resources (22), conflicts of interest between investigators and companies (23), and the role of the media (24) are also relevant here.”
Background
Infrastructure of Pharmaceutical Research and Development in Japan
Ono, S., Kodama, Y., & Nagao, T. (2001) · The Annals of Pharmacotherapy · doi:10.1345/aph.1a029 · Cited by 1
Selling, or Selling Out?
Lippman, A. (2000) · doi:10.1016/s0849-5831(16)30130-6 · Cited by 1
Ethical Issues and Challenges Facing the Pharmaceutical Industry
Eaton, M. L. (2007) · Elsevier eBooks · doi:10.1016/b0-08-045044-x/00026-2 · Cited by 1
The clinical research process: building a system in harmony with its users.
Koski, G. (2007) · Cancer treatment and research · doi:10.1007/978-0-387-33225-3_15 · Cited by 1
The politics of research impact: academic perceptions of the implications for research funding, motivation and quality
Chubb, J., & Reed, M. S. (2018) · British Politics · doi:10.1057/s41293-018-0077-9 · Cited by 106
Ensaios clínicos: capacitação nacional para avaliação de medicamentos e vacinas
Quental, C., & Salles, S. (2006) · doi:10.1590/s1415-790x2006000400002
Ethical Issues in Outsourcing: The Case of Contract Medical Research and the Global Pharmaceutical Industry
Adobor, H. (2011) · Journal of Business Ethics · doi:10.1007/s10551-011-0964-0
“Each day’s delay in gaining FDA approval of a drug, the manufacturer loses, on average, $1.3 million in potential revenue (Bodenheimer 2000).”
BackgroundInfluential
The involvement of professional medical writers in medical publications: results of a Delphi study
Force, A. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x25569
“314 Medical writing Delphi study © 2005 LIBRAPHARM LTD – Curr Med Res Opin 2005; 21(2) recognised outside of our own profession.”
BackgroundInfluential
Public Health Institutions, Clinical Research and Protection System of Patients’ Rights: An Impact Evaluation of Public Policy
Ippoliti, R., & Falavigna, G. (2012) · Public Organization Review · doi:10.1007/s11115-012-0208-5
Enabling equitable open access to commercially funded research publications
Schmidt, A., Winchester, C. C., Skobe, C., Stothard, D., & Topol, E. J. (2026) · PLoS Medicine · doi:10.1371/journal.pmed.1005207
“…ethos, and there has historically been skepticism towards for-profit research, sometimes justifiably so, owing to documented cases in which commercial interest influenced study design, data interpretation, publication practices and research independence in commercially funded research [12].”
Results of Randomized Controlled Trials of Platelet-Rich Plasma in Lower Extremity Tendinopathy Are Not Influenced By Industry Sponsorship.
Biedermann, B. M., Fathi, A., Kotlier, J. L., Lamb, C. J., Ahmad, A., Bolia, I. K., Mayfield, C., Petrigliano, F., & Liu, J. N. (2024) · Arthroscopy: The Journal of Arthroscopy And Related · doi:10.1016/j.arthro.2024.04.015
Publishing industry-sponsored studies.
Salonia, A., & Capogrosso, P. (2023) · Journal of Sexual Medicine · doi:10.1093/jsxmed/qdad003
Comparing the clinical trial characteristics of industry-funded trials and non- industry-funded trials
Hughes, E., Bakel, T. V., Raudanskis, A., Ray, P., Hodzic-Santor, B., Purohit, U., Sacks, C. A., & Fralick, M. (2023) · medRxiv · doi:10.1101/2023.03.24.23287707
“Among physicians, these documented instances have fostered mistrust in industry-sponsored trials.(8) One well-cited”
Neglected Diseases: Why Do Some Major Diseases Receive Less Attention Than Others?
Morris, B. (2020) · McGill Journal of Medicine · doi:10.26443/mjm.v8i2.676
VIOLATING THE BASIC TENETS OF CARE – LOOKING BACK ON YEARS OF EVIDENCE BASED MEDICINE FROM AN ONCOLOGIST'S VIEWPOINT
Basu, B. (2020) · doi:10.36106/gjra/1709872
Mechanisms and funding opportunities in genitourinary cancer clinical research.
Ryan, C. (2019) · Urologic oncology · doi:10.1016/j.urolonc.2018.05.024
Medicine and society
Malina, D., Bothwell, L. E., Greene, M., Podolsky, S., & Jones, M. (2019) · Oxford Handbook of Medical Sciences · doi:10.4324/9780429035456
“54 They have contributed to a shift in principal investigators in U.S. trials away from physician-scientists in academic teaching hospitals and toward nonacademic physicians working in the private sector on a contract basis.”
Preface to the Paperback Edition
Finchelstein, F. (2019) · Saudi Arabia · doi:10.1525/9780520911666-002
The Impact of Source of Funding on the Outcome of Clinical Trials in India
Ruqsana, B. (2018) · Arthaniti-Journal of Economic Theory and Practice · doi:10.1177/0976747918795224
“Studies by Ridker and Torres (2006) and Bourgeois et al. (2010) also found that trials conducted by profit organisations are more likely to be multicentric.”
BackgroundResultInfluential
Editorial Comment: Industry Payments to Urologists in 2014: an Analysis of the Open Payments Program
Bandari, J., & Jacobs, B. (2017) · Urology Practice · doi:10.1016/j.urpr.2016.07.016
Ethical Relation between Physicians and Pharmaceutical Industries in the Perspectives of Bangladesh
Alam, S., Saman, N., Hallaj, M., Alam, J., & Majumder, S. (2015) · doi:10.3329/bioethics.v6i1.24397
Management of Clinical Trial Agreements
Pfeiffer, J. P., & RICHMOND, F. J. R. (2014) · Therapeutic Innovation & Regulatory Science · doi:10.1177/2168479014551645 · Cited by 1
Rebuttal from Drs Greenberg and Vender.
Greenberg, S., & Vender, J. (2014) · Chest · doi:10.1378/chest.14-0686
Conflicto de intereses en investigación
Restrepo, P. A. (2014) · doi:10.22507/pml.v9n2a3
Conflict of interest in American neurology and neurological societies
Mitsumoto, H. (2014) · doi:10.1111/ncn3.90
Sociología de la evaluación médica. Problemas metodológicos y contexto socioeconómico de los ensayos clínicos
Carrión, J. J. S. (2013) · Papers Revista de Sociologia · doi:10.5565/rev/papers/v99n1.539
“…—CROs) y las organizaciones de gestión del lugar (Site-Management Organizations —SMOs), que han alterado completamente el panorama de los ensayos clínicos, «forzando a los centros médicos académicos a repensar su participación en la investigación financiada por la industria» (Bodenheimer, 2000)6.”
Background
Exploring the Role of Medical and Consumer Articles in the Diffusion of Information related to Medical Change
Genuis, S. (2013) · doi:10.29173/cais281
“…the medical community through its considerable influence on academia and research: industry influences research questions that are chosen for study, methodology, data analysis, and diffusion of findings (Bekelman, Li, and Gross 2003; Bodenheimer 2000; Davidoff et al. 2001; Lexchin et al. 2003).”
Background
Getting Started
Peat, J. K., Elliott, E. J., Baur, L. A., & Keena, V. A. (2002) · Wiley eBooks · doi:10.1002/9781118708019.ch2 · Cited by 1
Advancements in Medical Statistics Promote Economies of Scale
Dellinger, A. E. (2013) · Journal of Biometrics & Biostatistics · doi:10.4172/2155-6180.s7-e001
Conflict of interest policies and disclosures in Journals
Alfonso, F., Timmis, A., Ambrosio, G., Ector, H., Kulakowski, P., Vardas, P. E., & Pinto, J. (2012) · Cardiovascular Medicine · doi:10.4414/cvm.2012.01657
Is There A Lack Of Ethical Integrity In Drug Clinical Trials
Lemmens, T. (2010) · doi:10.1377/hlthaff.2010.0542
Key Personnel and “Long Distance” Settings: Determining Who Must Report Financial Conflict of Interest
Lynch, J., & Lindsell, C. J. (2010) · Accountability in Research · doi:10.1080/08989621.2010.493096
“COI can bias research, harm patients, and damage the public’s trust in the research enterprise (Blumenthal, 2003; Bodenheimer, 2000; Campbell et al., 2006; DeAngelis, 2000; Kass et al., 1996; Nabel, 2006).”
Background
Shackling Innovation The Regulation of Industry- Supported Clinical Trials
Fry-Revere, S., Ray, M., & Malmstrom, D. (2010) · doi:10.2139/ssrn.2713171
Fixing The “Broken Pipeline” Of AMC Scientists
Feldman, A. (2009) · Productivity Press eBooks · doi:10.1201/9781439816608.ch4
Relationships with the drug industry: Build trust based on good science
Gottlieb, S. (2009) · British medical journal · doi:10.1136/bmj.b234
“A large part of the industry’s current problems stems from the way its relationship with academic physicians and medical institutions has evolved over the past few decades. Formerly, the industry depended on academic doctors to conduct basic and clinical research. Now more of that work is done in house.”
Background
Konzept und Evaluierung der Münchner Prüfarztkurse
Albertsmeier, M., Faist, E., Thasler, W., Brandenburg, F., & Jauch, K. (2009) · Der Chirurg · doi:10.1007/s00104-008-1652-1
Science and ethics in publications in Psychiatry: the role of conflicts of interest
Mendlowicz, M. (2008) · doi:10.1590/s0101-81082008000400005
Firm boundary decisions: the market for health-related R&D services with an empirical case study for Germany
Baumann, O., & Grupp, H. (2008) · doi:10.1007/s10368-008-0116-x
“More applied work discussed ethical issues in RD Chopra 2003), pharmaceutical contract research (Haussler and Helberger 2001), issues of health care structure, financing, and academic RD Azoulay 2004), or potential options for health care reforms (Sachverstandigenrat 2003; Augurzky et al. 2004; Oberender et al. 2006).”
Pappworth's Guinea Pigs
Elliott, C. (2008) · doi:10.1017/s1745855208006078
STATE MEDICAL BOARD RESPONSES TO AN INQlJIRY ON PHYSICIAN RESEARCHER MISCONDUCT
Kruszewski, S., Paczynski, R., & Bialy, M. (2008) · Journal of Medical Regulation · doi:10.30770/2572-1852-94.1.16
Spiralling Medical Costs: Why Canada Needs NICE Medicine
Temple, N. J. (2007) · Healthcare policy · doi:10.12927/hcpol.2007.19390 · Cited by 3
Response to the letter by Williams et al.
Bertolini, G., Rossi, C., Anghileri, A., Livigni, S., Addis, A., & Poole, D. (2007) · Intensive Care Medicine · doi:10.1007/s00134-007-0711-2
“Moreover, it is well known that biases in sponsored trials may exist on multiple levels, and some suggest that the role of industry should be restricted to the funding of trials, while the design, conduct, analysis, and reporting should be left to independent researchers [10, 11].”
Background
Strategies for the administration of a clinical trials infrastructure: lessons from a comprehensive cancer center.
Zwelling, L., & Brunelli, C. A. (2007) · Cancer treatment and research · doi:10.1007/978-0-387-33225-3_14
The Conundrum of Office-Based Clinical Trials
Scott, L. (2007) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.01027.x
“But could there be other incentives for the sponsor, and in particular, can setting up and conducting a trial in a private setting be done with less scrutiny? Might the sponsor have more control over outcome data and its publication? Is the commercial or central IRB going to provide the same level of oversight as the…”
Background
Tricks of the Trade
Scott, T. (2006) · Ethical Human Psychology and Psychiatry · doi:10.1891/ehpp.8.2.133
“In 1991, it was 80% (Bodenheimer, 2000).”
Practice-Based Clinical Research and Ethical Decision Making-Part I: Deciding Whether to Incorporate Practice-Based Research into Your Clinical Practice
Chen, D. T., & Worrall, B. B. (2006) · Seminars in Neurology · doi:10.1055/s-2006-933317
“Sixty percent of industry research dollars were allocated to community-based studies by the end of the 1990s.(37) Industry increasingly relies on for-profit intermediary companies such as contract research organizations (CROs) and site management organizations (SMOs) to manage their studies and find less costly venues…”
Background
Practice-Based Clinical Research and Ethical Decision Making-Part II: Deciding Whether to Host a Particular Research Study in Your Practice
Chen, D. T., & Worrall, B. (2006) · doi:10.1055/s-2006-933318
RESPONSE TO DR. BECKER
Beck, J. C. (2005) · doi:10.1111/j.1532-5415.2005.t01-2-53384_5_3.x
RESPONSE LETTER TO DR. BECKER
Weeks, W. B., & Wallace, A. (2005) · doi:10.1111/j.1532-5415.2005.t01-1-53384_5_2.x
Clinical arithmetic
Currie, C. (2003) · British medical journal · doi:10.1136/bmj.327.7429.1418
The Lancet is my hero; I shall not want.
Worthley, L. (2003) · Critical Care and Resuscitation · doi:10.1016/s1441-2772(23)00867-0
Partnerships in Biomarker Research
Downing, G. J. (2003) · Drugs and the pharmaceutical sciences · doi:10.1201/9780203911235.ch12
Where do we go from here? Relations between the medical profession and the pharmaceutical industry
Alpert, J. (2003) · Current Cardiology Reports · doi:10.1007/s11886-003-0043-y
Industry sponsored clinical trials and conflict of interest : implications for policy
Baird, P. (2002) · Open Collections · doi:10.14288/1.0048357
“21 For example, if a new drug is compared with a lower dose of a competing product, or with a poorly absorbed preparation, the new drug may look better.(22) Patient selection also can make a big difference - if a drug is tested in patients who are younger and healthier than the patients who typically have the disease,…”
Background
Scientific data from clinical trials: investigators' responsibilities and rights.
Polk, H., Bowden, T., Rikkers, L., Balch, C., Organ, C., Murie, J., Pories, W., Buechler, M., Neoptolemos, J., Fazio, V., et al. (2002) · Annals of Surgical Oncology · doi:10.1016/s1072-7515(02)01241-3
Scientific data from clinical trials: investigators' responsibilities and rights.
Polk, H., Bowden, T., Rikkers, L., Balch, C., Murie, J., Pories, W., Buechler, M., Neoptolemos, J., Fazio, V., Schwartz, S. I., et al. (2002) · Journal of the American College of Surgeons · doi:10.1245/aso.2002.9.5.421
Editorial commentary on scientific fraud
Bland, K. (2002) · Annals of Surgical Oncology · doi:10.1007/bf02557259
The Crisis in Local Institutional Review Boards
Siegel, J., Vaughn, A., & Baszczewski, E. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-136-5-200203050-00018
The crisis in local institutional review boards.
Nagy-Agren, S. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-136-5-200203050-00020
The François Rabelais School of Medicine
Anderson, J. C. (2001) · British medical journal · doi:10.1136/bmj.323.7327.1456
Uses of error: more chefs.
Lauer, M. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06659-4
Concerns/questions about sedation and computed tomography scans.
Lalwani, K., & McGraw, T. (2001) · Pediatrics · doi:10.1542/peds.108.3.817-a
Migraine treatment.
Fenster, D. L. (2001) · Pediatrics · doi:10.1542/peds.108.3.817a
Is JPGN a Scientific or a Medical Journal?
(2000) · Journal of Pediatric Gastroenterology and Nutrition - JPGN · doi:10.1002/j.1536-4801.2000.tb02800.x
Institutional Corruption of Medical Knowledge Production
Laskai, A. (2020) · Studies of organized crime · doi:10.1007/978-3-030-44790-8_6 · Cited by 1
Undue Pharmaceutical Industry Influence in Medical Profession
Laskai, A. (2020) · Studies of organized crime · doi:10.1007/978-3-030-44790-8_2
Studien bei Kindern und Jugendlichen
Kölch, M., & Lippert, H. (2020) · Springer Reference Medizin · doi:10.1007/978-3-662-49289-5_93-1
Human Consideration vs. Business Orientation
Pulapa, S. R. (2020) · Business Ethics and The Bhagavad Gita · doi:10.1007/978-3-030-45630-6_6
The Budget
Omer, S., & Bakaeen, F. (2020) · Clinical Trials · doi:10.1007/978-3-030-35488-6_13
Clinical Trials
Pawlik, T., & Sosa, J. (2020) · Success in Academic Surgery · doi:10.1007/978-3-030-35488-6
References
(2020) · Elsevier eBooks · doi:10.1016/b978-0-12-386935-7.09998-9
Ethical Considerations in Acute Renal Replacement Therapy
Zamperetti, N., Vergano, M., Formica, M., & Livigni, S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-44942-7.00148-5
Funding and Bias
Bartolo, C. A. D., & Braun, M. (2017) · Springer eBooks · doi:10.1007/978-3-319-49547-7_2
Chapter 38 – Industry-Sponsored Clinical Research in Academia
Biaggioni, I. (2017) · doi:10.1016/b978-0-12-802101-9.00038-7
Evaluation of Informed Consent Documents used in Critical Care Trials
Atwere, P. (2015) · uO Research (University of Ottawa) · doi:10.20381/ruor-4033
Building Your Clinical Trial Research Team
Gosnell, J. (2014) · Success in academic surgery · doi:10.1007/978-1-4471-4679-7_1
Infraestrutura científica e tecnológica para apoio ao CEIS — segmento biofarmacêutico
Quental, C., Gadelha, C. A. G., Maldonado, J., Costa, L., & Vargas, M. (2013) · doi:10.7476/9788581100197.0007

Authors: Bodenheimer, T.
Corresponding author: Bodenheimer, Thomas
ORCID: Bodenheimer, Thomas
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2000-05-18
Volume: 342
Issue: 20
Pages: 1539-1544
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejm200005183422024
OpenAlex: W2337821671
Cited by: 765
References: 0
Citations by year: 2026: 2 · 2025: 2 · 2024: 4 · 2023: 8 · 2022: 10 · 2021: 10 · 2020: 17 · 2019: 11 · 2018: 14 · 2017: 18 · 2016: 11 · 2015: 14 · 2014: 20 · 2013: 31 · 2012: 34
FWCI: 51.34
Type: journal article
Language: en
Open access: closed
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
DigitalGeorgetown (Georgetown University Library) (submittedVersion)
Topics: Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health and Medical Research Impacts
Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
Keywords: clinical investigators, pharmaceutical industry, contract research organizations, academic medical centers, clinical trials, conflicts of interest, drug development
MeSH terms: Academic Medical Centers, Authorship, Clinical Trials as Topic, Drug Evaluation, Drug Industry, Interinstitutional Relations, Publishing, Research Support as Topic, Social Change, United States, United States Food and Drug Administration, Conflict of Interest, Drug Approval, Disclosure, Contracts, Biomedical Research

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Uneasy alliance—clinical investigators and the pharmaceutical industry

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Metadata

Record

About these checks